Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

BACKGROUND: In patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y(12) inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa inhibitors are still needed. Ticagrelor and eptif...

Descripción completa

Detalles Bibliográficos
Autores principales: Marian, Moazez J., Alli, Oluseun, Al Solaiman, Firas, Brott, Brigitta C., Sasse, Mark, Leesar, Tara, Prabhu, Sumanth D., Leesar, Massoud A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669172/
https://www.ncbi.nlm.nih.gov/pubmed/28611098
http://dx.doi.org/10.1161/JAHA.117.005562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669172/
https://www.ncbi.nlm.nih.gov/pubmed/28611098
http://dx.doi.org/10.1161/JAHA.117.005562

Ejemplares similares